Back to search
FDAFDA · Food and drugs·Recall number D-0248-2019

ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA. NDC: 66733-958-23

Published November 21, 2018 · Recall initiated: November 8, 2018

Summary

FDA records drug Class III recall D-0248-2019, published November 21, 2018 and initiated November 8, 2018. Recalling firm: Eli Lilly & Co; Status: Terminated; Reported quantity: 9,380 vials; Lot: Lot number: C1700167, exp 9/2020. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Missing label; potential for missing primary container label on the vial.

What to do

Voluntary: Firm initiated · Letter

Get an email if ERBITUX has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ERBITUX
Manufacturer
Eli Lilly & Co
Distributor
AL, AZ, CA, KS, LA, MS, OH, OR, TN, TX and Puerto Rico
Lot
Lot number: C1700167, exp 9/2020
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA. NDC: 66733-958-23 recalled?

Yes. FDA published recall D-0248-2019 on November 21, 2018. Reported hazard: Labeling: Missing label; potential for missing primary container label on the vial.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ERBITUX.